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Abstract
Background: Previous cohort studies demonstrate diabetes as a risk factor for tuberculosis (TB) disease. Public
Health England has identified improved TB control as a priority area and has proposed a primary care-based
screening program for latent TB.
We investigated the association between diabetes and risk of tuberculosis in a UK General Practice cohort in order
to identify potential high-risk groups appropriate for latent TB screening.
Methods: Using data from the UK Clinical Practice Research Datalink we constructed a cohort of patients with
incident diabetes. We included 222,731 patients with diabetes diagnosed from 1990–2013 and 1,218,616 controls
without diabetes at index date who were matched for age, sex and general practice. The effect of diabetes was
explored using a Poisson analysis adjusted for age, ethnicity, body mass index, socioeconomic status, alcohol intake
and smoking. We explored the effects of age, diabetes duration and severity. The effects of diabetes on risk of
incident TB were explored across strata of chronic disease care defined by cholesterol and blood pressure
measurement and influenza vaccination rates.
Results: During just under 7 million person-years of follow-up, 969 cases of TB were identified. The incidence of TB
was higher amongst patients with diabetes compared with the unexposed group: 16.2 and 13.5 cases per 100,000
person-years, respectively. After adjustment for potential confounders the association between diabetes and TB
remained (adjusted RR 1.30, 95 % CI 1.01 to 1.67, P = 0.04). There was no evidence that age, time since diagnosis
and severity of diabetes affected the association between diabetes and TB. Diabetes patients with the lowest and
highest rates of chronic disease management had a higher risk of TB (P <0.001 for all comparisons).
Conclusions: Diabetes as an independent risk factor is associated with only a modest overall increased risk of TB
in our UK General Practice cohort and is unlikely to be sufficient cause to screen for latent TB. Across different
consulting patterns, diabetes patients accessing the least amount of chronic disease care are at highest risk for TB.
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Background
In the UK, rising rates of tuberculosis (TB), particularly
in socially disadvantaged groups including migrants, are
of great public health concern. London has the highest
TB incidence of any western European capital [1]. There
is evidence that reactivation of latent disease accounts
for a large number of new TB diagnoses in the UK pro-
viding an argument for screening and treating latent dis-
ease in high-risk groups to help reverse the UK’s
increasing incidence of TB [1, 2]. An effective TB con-
trol program that targets latent disease within a UK
population will need to define high-risk groups and
strategies for accessing and screening them. It could be
that the role of diabetes as an independent risk factor
for TB disease, or identification of subgroups of diabetic
patients at particularly high risk, might inform any fu-
ture UK screening and treatment policy.
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Previous cohort studies have demonstrated an increased
risk for TB disease in people with diabetes. The most re-
cent meta-analysis that included three cohort studies
showed a rate ratio of 3.11 (95 % confidence interval (CI)
2.27 to 4.26) for pulmonary TB associated with diabetes
[3]. None of these studies were based in a UK population
and two of the studies were in patients with renal failure,
which is an independent risk factor. There has been one
previous cohort study in a UK population [4] using two
linked hospital based datasets from Oxford which found
rate ratios of 1.83 (CI 1.26 to 2.60) and 3.11 (CI 1.17 to
7.03) for active TB disease comparing patients with dia-
betes with a reference hospital cohort. There has been no
previous large cohort study in the general UK population
exploring the association between diabetes and TB risk,
which has also been able to include the effects of poten-
tially important confounders.
We used a large UK representative general practice
database to assess the overall risk of TB comparing people
with and without diabetes and to explore whether factors
relating to the patient, diabetes condition or accessing
primary health care further defined a high risk group
for TB, whilst adjusting for important confounding risk
factors.
Methods
We undertook a matched cohort study to investigate the
incidence of TB in patients with and without diabetes.
Clinical Practice Research Datalink
The UK Clinical Practice Research Datalink (CPRD)
contains anonymised data from clinical general practice
records of more than 15 million patients. Data on demo-
graphic, diagnostic, prescription, referral, clinical test re-
sults and pertinent lifestyle measures are included in the
records. Data collection started in 1987 and currently
the database contains information from the medical re-
cords of 680 UK participating general practices where
there are 7 million patients currently registered. The in-
formation contained on the database undergoes regular
rigorous quality checks.
Hospital episode statistics
Hospital Episode Statistics (HES) data include informa-
tion on English NHS Trust hospital admissions from
1989 and outpatient clinic attendances from 2003. Key
diagnostic (using international classification of diseases
codes, ICD-10) and demographic data are contained in
this database and hospital data for patients residing
within the English region of the CPRD are eligible to be
linked with their CPRD general practice record. We used
HES ethnicity data.
Study participants
We identified a cohort of patients within the CPRD with
incident diabetes (types 1 and 2 included), ≥5-years old,
who had their first recorded diagnosis for diabetes in the
study period 1 January 1990 to 31 December 2012. Pa-
tients were identified using National Health Service
(NHS) Read codes, which are a coded thesaurus of clin-
ical terms and diagnoses [5]. A diagnosis of diabetes
was considered incident if the Read code was first re-
corded on a date at least 12 months after the patient’s
current practice registration date, to avoid including
prevalent cases recorded when patients register [6]. The
incident date was taken as the date of the first diabetes
diagnostic Read code. Patients were excluded if they had a
secondary, gestational or genetic cause of diabetes re-
corded or had codes indicating the earlier diabetes Read
code was incorrect (example “ceased” or “not” codes).
Once this initial cohort of patients with incident diabetes
was created, further data quality checks were made
excluding those who did not have a feasible temporal
sequence for dates of birth, registration and death
(Fig. 1).
The cohort of patients identified with incident diabetes
was initially divided into type 1 and 2 diabetes contain-
ing definite, probable and possible categories based on
their diagnostic Read code and number of contradictory
codes according to methods previously published by
De Lusignan et al. [7] The cohorts were then further
refined using algorithms including patient age at diag-
nosis, prescriptions for insulin and other anti-diabetic
drugs (OAD), body mass index (BMI) and ethnicity
data, where this was available, based on methods first
described in the Royal College of General Practitioners’
report of coding and classifying diabetes [8] (Additional
files 1 and 2).
An unexposed matched cohort was created, composed
of those who did not have a prevalent diagnosis of dia-
betes on the matched index date, which also had to fall
12 months on or after their current registration date. Up
to six unexposed patients were randomly selected and
matched for age +/− 5 years, gender and General Prac-
tice with every exposed patient. Patients in the unex-
posed group could become diabetic during the study
period and would then join the exposed cohort for the
remainder of their follow-up. This was done so that our
exposed cohort was not compared against an unusually
healthy unexposed group who were never at risk of dia-
betes. This design helps control for unmeasured con-
founding lifestyle factors and allows for time dependent
analyses. Patients included in the unexposed cohort had
to have at least one face-to-face consultation or acute
prescription recorded within the 12 months before or
after their matched index date to ensure they were active
in their follow-up. The unexposed cohort was subject to
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the same data quality checks and exclusions as the ex-
posed cohort (Fig. 2).
Tuberculosis outcome
A list of Read codes for all forms of tuberculosis was
developed (available on request). Prescriptions for anti-
tuberculosis drugs was not used in developing or later
validating cases of TB identified by diagnostic Read codes
as these medications singly prescribed are not specific to
active TB disease which is treated by secondary care spe-
cialists in the UK. Both exposed and unexposed patients
were allowed to have had TB recorded before their index
or matched index date but there was a lag period of 2 years
after the last coding of TB before a subsequent coding of
TB would be considered as a new diagnosis. Any part of
this lag period which occurred after the (matched) index
date was not included as follow-up time in order to avoid
time-related bias [9] (see Fig. 3).
Confounders and effect modifiers
We considered potential confounders including age, gen-
der, BMI, alcohol intake, smoking status, socioeconomic
status and ethnicity. Chronic renal failure was not consid-
ered as a confounder as it is on the causal pathway. Ex-
posure to steroid medication was also not included as
secondary diabetes Read codes were excluded. As age and
gender were used in the matching process, we only in-
cluded age in our final models to adjust for any residual
confounding by this factor. BMI, alcohol intake and smok-
ing status were taken from data recorded closest to index
or matched index date. Ethnicity data was generated using
both CPRD and HES data for English patients based on al-
gorithms produced by one of the authors (RM) described
previously [10]. See Additional file 3 for further method-
ology details on variable construction.
To explore any possible ascertainment bias from likely
increased consultation rates in patients with diabetes, we
Patients with medical codes for 
diabetes in study period
(1st Jan 1990-31st Dec 2012) 
N=530,994
Patients with minimum 12 
months of registration prior 
to diabetes diagnosis 
N=234,098
Excluded 188 as diabetic 
diagnosis was after death 
date
First episode of diabetes 
in study period 
N=462,744
Episode of diabetes 
occurring within 
current registration
N=289,513
Patients are acceptable quality 
N=283,092
Patients registered as male or 
female and ≥ 5 years of age at  
first diabetes diagnosis  
N=281,827
No therapy file 
N=228
Excluded 11,164 with “other 
diabetes codes”: genetic, 
secondary, ceased, not 
diabetes, gestational
N=222,934
N=222,934
Final cohort of
patients with
incident diabetics 
N=222,731
Therapy file but no 
diabetic therapy 
N=65,777
Diabetic therapy 
appears before 
medical diagnosis 
N=12,015
Therapy file and 
diabetic therapy 
N=156,726
Excluded 15 after 
adjusted follow-up 
date>end date 
N=222,746
Fig. 1 Flow chart of patients with incident diabetes included in the study
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studied the effect of diabetes within strata of yearly con-
sultation rate and total consultation number. As consult-
ation rates capture the severity of disease we did not
adjust for this, to avoid adjusting for diabetes exposure.
Yearly consultation rate was generated using the same
face to face consultation codes used to define active pa-
tients and the denominator of follow-up time adjusted
for any possible time-related bias from previous TB diag-
noses. Similarly, each patient’s total consultation number
was constructed for the same period.
We explored the effect of health care utilisation to in-
vestigate effects of access to care to reduce ascertainment
bias for diabetes patients more likely to have regular pri-
mary care follow-up. Health care utilisation was captured
by studying rates of blood pressure and cholesterol meas-
urement and influenza vaccination. These three measures
are incentivised in UK General Practice and patients with
diabetes should receive these interventions at least once
per year. These specific factors were chosen to capture
health care utilisation without the same inherent limita-
tion of consultation rate, which is dependent on diabetes
severity.
Statistical analysis
Follow-up time started from the index or matched-index
or at the end of any potential immortal time period (Fig. 3).
Follow-up ended at the earliest occurrence of first TB
diagnosis post index date, transfer out of the practice, last
practice data collection, death from any cause or the end
of the study, 31 December 2012.
Initial univariate analysis of diabetes exposure and the
outcome of TB were explored by dividing the exposed co-
hort into type 1 and type 2 diabetes categories to ascertain
All patients from the January 
2013 build of CPRD
N=12,597,957
Patients eligible as potential 
controls (includes patients 
with incident diabetes for 
period previous to their 
diagnosis)
N=10,695,272
Matching
Patients’ data acceptable 
quality:
gender: male or female
crd1<death date
crd<end of study
uts2<transfer out date
uts<death date
uts<end of study
N=10,597,293
N=1,330,832
Excluded 262,021 with 
prevalent or “other” diabetes 
codes: genetic, secondary, 
ceased, not diabetes, 
gestational
Matched 6:1 for:
practice, gender, age +/- 5 years
and minimum registration period 
1 year
N=10,695,272
Final cohort of 
control patients
N=1,218,616
Excluded 
112,110 inactive 
in follow-up
Excluded 106 after 
adjusted follow-up 
date>end date
Fig. 2 Flow chart of unexposed control patients included in the study. Crd1: current registration date in practice. Uts2: practice data up to
standard quality
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number of events in each and the possibility of further ex-
ploring these subtypes in the multivariable analysis.
We used a Poisson regression model for the adjusted
rate ratio of first diagnosis of TB comparing patients with
diabetes with their matched unexposed cohort. We as-
sumed that UK incidence rates of TB do not vary rapidly
over time. An unmatched analysis was used as this does
not introduce bias when analysing matched cohort studies
[11]. The analysis model was developed guided by the pos-
tulated causal relationships between variables (Fig. 4). Var-
iables were kept in the model if they changed the point
estimate for the rate ratio of TB for our exposed cohort
Diabetes/matched 
index date
Diabetes 
index date TB episode
TB outcome
Immortal me
Follow-up me
Fig. 3 Assignment of follow-up time allowing for previous tuberculosis diagnosis
Diabetes Tuberculosis
Alcohol Smoking BMI
IMD
Ethnicity
Consultation rate
Ascertainment 
bias
BMI: body mass index; IMD: index of multiple deprivation
Fig. 4 Causal diagram of associations between diabetes, tuberculosis and confounders
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and with the addition of each variable we assessed for pos-
sible collinearity by studying changes in standard errors.
A priori effect modification of the relationship between
diabetes and TB by age, ethnicity, duration of diabetes and
within strata of consultation pattern was explored.
To explore the effect of diabetes exposure on absolute
tuberculosis incidence we used the Poisson model devel-
oped previously to predict event rates amongst patients
at most and least risk of TB according to our baseline
bivariate analyses.
A pre-specified exploration of the effect of severity of dia-
betes was undertaken by comparing the adjusted rate ratios
of TB incidence for patients with type 2 diabetes in differ-
ent insulin treatment categories, comparing those requiring
insulin and those without insulin (treated with other anti-
diabetic drugs or diet alone) with a matched non-exposed
cohort. A time-updated analysis was used (see Additional
file 3 for a full description of the methodology).
The effect of glycaemic control was studied using a
post-index mean value for HbA1c, calculated for all pa-
tients with type 2 diabetes and TB rates were calculated
within strata of glycaemic control. Algorithms were devel-
oped to identify and convert HbA1c units from DCCT
(Diabetes Control and Complications Trial) percent units
to the more recent IFCC (International Federation of
Clinical Chemistry) mmols/mol units.
All primary analyses were performed on a complete-
case basis. Further post hoc and sensitivity analyses are
described in Additional file 3. All data analyses were car-
ried out using STATA 13 MP.
Protocol and ethical approval
The study received ethical approval under protocol
number 13_014 by the Independent Scientific Advisory
Committee for the Medicines and Healthcare products
Regulatory Agency for patient-level NHS database re-
search and the LSHTM Research Ethics Committee (ref-
erence 6352).
Results
Study population and baseline characteristics
From 530,994 patients identified with a diabetes Read
code recorded within the study period, 222,731 patients
with incident diabetes were included in this study, com-
prising 6,186 patients with type 1 and 216,545 patients
with type 2 diabetes (see Additional files 1 and 2). These
were matched to a total of 1,218,616 patients who were
unexposed to diabetes at their matched index date, 82,208
(6.74 %) of whom went on to have a diabetes Read code
and hence joined the exposed cohort for the remainder of
their follow-up. On initial matching 98.59 % of the ex-
posed cohort had 6 possible matched controls with only
76 patients having no matched controls. After excluding
these and controls that failed quality checks and were not
active in their follow-up, 92.77 % of the exposed cohort
had ≥5 matched controls.
The median follow-up time was 4.4 years (interquartile
range 1.9 to 7.8 years) for patients with incident diabetes
and 3.8 years (interquartile range 1.6 to 7.0 years) for
matched control patients. In total, the diabetes cases and
their matched controls contributed a little less than seven
million person-years of follow-up. Amongst the cohort
with diabetes, 66,005 (29.6 %) had no anti-diabetic medi-
cation recorded in their therapy files. In those patients
with anti-diabetic prescriptions, 133,503 (85.2 %) had pre-
scriptions for metformin singly or combined and 35,203
(22.4 %) had insulin prescriptions.
Baseline characteristics for patients with incident dia-
betes and the matched unexposed cohort are shown in
Table 1. There were considerable missing data for ethni-
city (45.3 %) and index of multiple deprivation (IMD)
(39.5 %) for the total cohort, although there were fewer
missing data for patients with diabetes. In total, 97,861
(43.9 %) patients with incident diabetes and 461,792
(37.9 %) of the matched unexposed cohort had complete
data on all variables and were used in the complete case
analysis. Patients with diabetes consulted more fre-
quently than their matched controls (P <0.001).
Effect of diabetes on tuberculosis incidence
A total of 969 TB outcomes were recorded during follow-
up and 2,376 (1.07 %) of the exposed and 13,867 (1.14 %)
of the unexposed had previous TB recorded. The inci-
dence of TB was higher amongst patients with diabetes
compared with a matched unexposed group, 16.2 and 13.5
cases per 100,000 person-years, respectively (Table 2).
After adjustment for potential confounders the association
between diabetes and TB incidence remained (adjusted
rate ratio 1.30, 95 % CI 1.01 to 1.67, P = 0.04).
The associations between diabetes and the potential
confounders with TB that were included in the adjusted
model are shown in Table 3.
There was only one TB outcome event in the follow-up
period of patients classified with type 1 diabetes; thus, in
all further analyses we used a cohort with both types of
diabetes combined or where stated only those with type 2
diabetes and their matched unexposed cohort.
The estimated absolute increase in TB incidence com-
paring patients with and without diabetes in those with
the highest baseline risk of TB (age >70 years, South Asian
ethnicity, non-drinkers, current-smokers, BMI <20 and in
the 5th IMD quintile) was an extra 206 cases per 100,000
person-years (Table 4).
Effect of age, duration of diabetes diagnosis and
consultation patterns
The median age for TB diagnosis was nearly five years
younger for patients with diabetes (67.5 years, IQR 58.5–
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Table 1 Characteristics of patients with incident diabetes and a matcheda non-exposed cohort
Characteristic Patients with diabetesb Patients without diabetesc
Number = 222,731 Number = 1,218,616
Age at entry in years
(Median, IQR) 62.9 (52.5–72.5) 63.6 (53.3–72.9)
Male gender
(number, %) 122,594 (55.0) 647,287 (53.1)
Smoking (number, %)
Non-smoker 82,856 (37.2) 525,881 (43.2)
Ex-smoker 93,491 (42.0) 404,929 (33.2)
Current smoker 42,414 (19.0) 244,247 (20.0)
Missing 3,970 (1.8) 43,559 (3.6)
Alcohol intake (number, %)
Non-drinker 31,232 (14.0) 134,862 (11.1)
Ex-drinker 12,151 (5.5) 44,158 (3.6)
Moderate drinker 145,695 (65.4) 793,877 (65.2)
Heavy drinker 18,843 (8.5) 99,444 (8.2)
Missing 14,810 (6.7) 146,275 (12.0)
BMI (number, %)
<20 4,648 (2.1) 50,404 (4.1)
20- < 25 29,973 (13.5) 347,150 (28.5)
25- < 30 70,949 (31.9) 418,421 (34.3)
≥30 105,789 (47.5) 242,928 (19.9)
Unknown 11,372 (5.1) 159,713 (13.1)
Ethnicity (number, %)
White 122,507 (55.0) 626,733 (51.4)
South Asian 5,326 (2.4) 12,979 (1.1)
Black 2,347 (1.1) 7,979 (0.7)
Mixed or Other 2,143 (1.0) 8,518 (0.7)
Missing 90,408 (40.6) 562,407 (46.2)
Index of Multiple Deprivation
1 – Least deprived 26,071 (11.7) 164,172 (13.5)
2 30,191 (13.6) 174,611 (14.3)
3 27,406 (12.3) 149,262 (12.3)
4 27,207 (12.2) 136,276 (11.2)
5 – Most deprived 24,080 (10.8) 113,147 (9.3)
Missing 87,776 (39.4) 481,148 (39.5)
Mean number of consultations per year
1st tertiled (0–6) 16,096 (7.2) 464,352 (38.1)
2nd tertile (7–12) 73,287 (32.9) 407,155 (33.41)
3rd tertile (13-maximum) 133,348 (59.9) 347,109 (28.5)
Total number of consultations
1st tertiled (1–15) 32,699 (14.7) 444,234 (36.5)
2nd tertile (16–49) 65,760 (29.5) 411,258 (33.8)
3rd tertile (50-maximum) 124,272 (55.8) 363,124 (29.8)
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75.4 years) compared with unexposed patients (71.9 years,
IQR 63.5–78.3 years, P <0.001, Wilcoxon rank sum
test). There was no evidence for an effect of age on dia-
betes risk for tuberculosis (P = 0.228), although there
were only small numbers of patients in the lowest age
strata (Table 5). There was no evidence for effect of
duration of diabetes diagnosis on risk of tuberculosis
(P = 0.375). To study possible interaction with ethnicity
the categories of black and mixed/other were combined
to provide sufficient TB events in each strata. There
was no evidence for a role of ethnicity in modifying the
effects of diabetes for tuberculosis risk (P = 0.894).
For consulting patterns, there was a suggestion that
diabetes had a greater effect on risk of TB for those who
consulted at the lowest rate and the effect of diabetes di-
minished with increasing consultation rates, but this pat-
tern was not statistically significant. Our results were
not changed by excluding those with follow-up shorter
than six months who might have unstable consultation
rates. A similar but statistically significant pattern was
seen when looking within strata of total consultation
number with the effect of diabetes conferring a greater
risk for TB in the group with the least number of con-
sultations in their follow-up (P = 0.003).
Across health care utilisation patterns there was strong
evidence (P <0.001) of differences in TB risk amongst dia-
betes patients, with patients accessing the lowest and
highest amounts of chronic disease health care being at
higher risk of TB, particularly in those with lower influ-
enza vaccination rates (Table 6).
Comparing insulin and non-insulin users within type 2
diabetes
There was an association between increasing severity of
type 2 diabetes and increasing TB risk as indicated by
time-dependent analyses comparing insulin users ver-
sus non-users in crude analyses with age adjustment
(P = 0.020), but this relationship did not remain after
full adjustment (Table 7).
Effect of glycaemic control in type 2 diabetes
In the subset of type 2 diabetes patients with Hba1c mea-
surements (198,227) compared with their matched unex-
posed controls, there was no evidence for increasing TB
risk with worsening glycaemic control (Table 8).
Post hoc and sensitivity analyses are described in
Additional file 4.
Discussion
Key findings
In this large UK population based cohort of patients with
incident diabetes we found only an overall modest 1.3 fold
increased risk of tuberculosis. We found no evidence for
higher relative increases in TB rates amongst diabetes pa-
tients of different age groups or ethnicities, longer duration
of disease, those using insulin or with worse glycaemic
control. There was strong evidence for differences amongst
diabetes patients with different health care utilisation
patterns. The highest risk of TB disease was amongst the
group least accessing chronic disease health care.
Table 1 Characteristics of patients with incident diabetes and a matcheda non-exposed cohort (Continued)
Length of follow-up in years
(Median, IQR) 4.4 (1.9–7.8) 3.8 (1.6–7.0)
Total person-years 1,172,829 5,767,599
aPatients with and without diabetes were matched for index date, age +/− 5 years, gender and practice
bDiabetes diagnosis defined as index date and start of follow-up
cPatients without diabetes on matched index date but may become diabetic in follow-up period
dTertiles defined in the overall cohort
BMI body mass index, IQR interquartile range
Table 2 Rates and adjusted rate ratios for all types of tuberculosis (TB) by exposure to diabetes
Age-adjusted Fully adjusted modela
Exposure status Number of TB cases/PYb Ratec (95 % CI) Rate ratio Rate ratio
(95 % CI) (95 % CI)
P* = 0.025 P** = 0.039
Patients without diabetes 779/57.68 13.51 (12.59–14.49) 1.00 1.00
Patients with diabetes 190/11.73 16.20 (14.05–18.68) 1.20 (1.02–1.40) 1.30 (1.01–1.67)
*P-value from Wald test, **P-value from likelihood ratio test
aModel adjusted for: age, alcohol, smoking, BMI, ethnicity, IMD
bPY: 100,000 person years at risk
cRate: per 100,000 person years
BMI body mass index, CI confidence interval, IQR interquartile range
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Comparison with other studies and explanation of
findings
Our study is the largest cohort study to date exploring the
association between diabetes and TB with individual-level
adjustment for important demographic and lifestyle fac-
tors. The finding of an overall increased risk of TB in
those with diabetes is in agreement with previous pub-
lished studies and reviews [12–29, 4, 30, 3, 31]. However,
in contrast we find only an overall small relative effect
from diabetes in our UK population. The most recent sys-
tematic review and meta-analysis [3] included eight case-
control studies with odds ratios ranging from 1.16 to 7.83
and a random effects analysis of the three included cohort
studies showed a three-fold increased risk of TB with dia-
betes (relative risk 3.11, 95 % CI 2.27 to 4.26). All three co-
hort studies included in the meta-analysis were conducted
in high TB incidence countries and two used cohorts of
renal transplant patients.
Since the most recent systematic review, we are aware
of seven more published analytical studies in humans
looking at the question of TB risk associated with dia-
betes, including two case-control [26, 27] and five cohort
studies [25, 28, 29, 4, 32] summarised in Additional file
5. Our finding of only a modest increase in risk of TB
with diabetes is in agreement with these more recent
studies. As study size increases there is a decrease in the
estimate for the association between diabetes and TB
seen for both cohort and case-control designs, even in
higher incidence countries. These differences could be
due to publication bias in earlier studies and/or the
adjustment for more confounding in later studies. Leung
et al. [25] used a cohort from a Hong Kong community
based health program for ≥65 year olds and were able to
adjust for demographic and lifestyle factors giving an
overall adjusted hazard ratio of 1.77 (1.41 to 2.24).
Dobler et al. [29] used a whole population cohort for
Australian citizens and adjusted for demographic and in-
digenous status and TB incidence in country of birth
using census aggregate data for the unexposed general
population cohort. They found a 1.4 fold increased risk of
TB in those with diabetes (RR 1.48, 1.04 to 2.10). The lar-
gest matched case-control study by Leegaard et al. [27] in
Denmark found no overall association between diabetes
and TB after adjusting for a range of chronic disease and
demographic indicators (OR 1.18, 0.96 to 1.45).
We report a median length of follow-up of 4.4 years
which is similar to that in previous studies and on the
whole, most of the patients included had reasonably
well-controlled diabetes. The largest cohort studies pre-
viously reported, Kim et al. [12] and Dobler et al. [29],
which were unable to adjust for individual confounding,
had study periods of two and six years, respectively. It
is possible that the risk of TB associated with well-
controlled diabetes only becomes manifest over much
Table 3 Univariate and multivariable associations between
diabetes and other risk factors for tuberculosis
Variable Crude rate ratio Adjusted rate ratioa
(95 % CI) (95 % CI)
No diabetes 1.00 1.00
Diabetes 1.20 (1.02–1.41) 1.30 (1.01–1.66)
Age (per 1 year increase) 1.02 (1.01–1.03) 1.03 (1.02–1.04)
Smoking
Non-smoker 1.00 1.00
Ex-smoker 1.23 (1.06–1.44) 1.27 (1.00–1.61)
Current smoker 1.73 (1.48–2.03) 1.67 (1.27–2.19)
Alcohol intake
Non-drinker 1.00 1.00
Ex-drinker 0.64 (0.44–0.94) 1.00 (0.58–1.73)
Moderate drinker 0.50 (0.42–0.59) 0.86 (0.65–1.13)
Heavy drinker 0.66 (0.51–0.85) 1.04 (0.69–1.59)
BMIb
<20 1.00 1.00
20- < 25 0.41 (0.33–0.51) 0.62 (0.42–0.90)
25- < 30 0.26 (0.21–0.32) 0.35 (0.24–0.51)
≥30 0.21 (0.17–0.27) 0.29 (0.19–0.45)
Ethnicity
White 1.00 1.00
South Asian 9.41 (7.48–11.84) 10.77 (7.84–14.81)
Black 3.47 (2.11–5.72) 2.28 (1.01–5.16)
Mixed or Other 2.84 (1.70–4.75) 2.50 (1.23–5.07)
Index of Multiple Deprivationc
1 – Least deprived 1.00 1.00
2 1.45 (1.10–1.91) 1.24 (0.89–1.72)
3 1.38 (1.03–1.84) 1.19 (0.85–1.67)
4 1.76 (1.33–2.33) 1.36 (0.97–1.90)
5 – Most deprived 2.31 (1.75–3.04) 1.47 (1.05–2.07)
Consultation rated
1st tertile (0–6) 1.00 N/A
2nd tertile (7–12) 2.08 (1.71–2.54)
3rd tertile (13-maximum) 4.58 (3.81–5.51)
Total number of consultationse
1st tertile (1–15) 1.00 N/A
2nd tertile (16–49) 0.54 (0.46–0.63)
3rd tertile (50-maximum) 0.26 (0.23–0.31)
aModel includes: diabetes, age, smoking status, alcohol status, BMI, ethnicity
and index of multiple deprivation
bBMI: body mass index in kg/m2
cIndex of multiple deprivation in quintiles and available for English
patients only
dConsultation rate defined as number of face to face consultations per year of
follow-up; tertiles in order of increasing consultation rate
eConsultation number defined as total number of face to face consultations
during patient follow-up; tertiles in order of increasing number of consultations
CI confidence interval, NA not available
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longer periods and we may possibly have under-estimated
long-term risks.
The relatively small effect estimate for TB risk from
diabetes found in our study could be due to the ability
to adequately control for important individual level con-
founding from lifestyle and demographic risk factors
using the CPRD. Our findings might also be a reflection
of a successful primary care service with good chronic
disease management and, therefore, reduction in attend-
ant infection complications from diabetes. In support of
this hypothesis, we see increased risks for TB disease from
diabetes in those with the highest and lowest chronic dis-
ease management. Diabetes patients most frequently
accessing chronic disease care could represent a group
with more uncontrolled disease where general practice
teams are seeking to improve diabetes management. The
group with the least health care utilisation from that
incentivised in UK General Practice for chronic disease
management, may have more uncontrolled diabetes and
have limited access to primary health care. The latter
group might form part of a wider hard to reach group
who are at increased risk of TB not only from diabetes but
from multiple social risk factors [33]. Of note, our findings
show diabetes patients receiving standard rates of chronic
disease care, which in part will reflect good diabetes con-
trol, are at no increased risk of TB compared against
patients without diabetes.
We did not find evidence for an effect of age, duration
of diabetes or ethnicity for TB risk in diabetes patients al-
though this could be due to type 2 error as we only had
very small numbers of TB cases in some diabetes sub-
groups and had missing data on important confounders.
Although some studies have found evidence for increasing
TB risk in younger diabetes patients [12, 15], other au-
thors have not [27, 29]. No previous studies have explored
the effect of duration of diabetes diagnosis on risk of TB
disease but if diabetes acts to increase the risk of TB infec-
tion or increases reactivation of latent disease, it would
seem probable that cumulative exposure to diabetes would
potentiate these risks.
The previous literature, using a variety of different
markers, show mixed results for the effect of diabetes se-
verity on the risk for TB. Leung et al. [25] stratified by
glycaemic status and found those with Hba1c <7 % had
no increased risk of TB compared with those without
diabetes, in contrast to the subjects with Hba1c ≥7 %
who were at 2.5 fold risk (HR 2.56, 1.95 to 3.35). Baker
et al. [28] used the number of diabetes complications to
explore the effect of diabetes severity and found that
those with treated diabetes and ≥2 complications com-
pared against a group without diabetes had a greater risk
of TB (RR 3.45, 1.59 to 7.90). Dobler et al. [29] explored
the effects of insulin use as a marker of severity and
found that those using insulin had 2.3-fold risk com-
pared against a general population cohort (RR 2.27, 1.41
to 3.66). In contrast, and coherent with our own data,
Leegaard et al. [27] found no evidence for an association
between TB risk and dysglycaemia. Again, this might re-
flect that diabetes patients managed in UK Primary Care
have very well controlled disease, not completely cap-
tured by mean Hba1c measurements and, therefore, re-
duced attendant risks from infection.
We aimed to compare the different types of diabetes
for risk of TB. The underlying hypothesis being that type
1 diabetes represents a more severe form of diabetes and
thus we might expect that it poses a greater risk for TB
infection if the relationship between diabetes and TB
risk is causal. Only the previous study by Leegaard et al
[27] defined and explored the risk of TB for a group
with type 1 diabetes. They classified patients <30-years
old using insulin monotherapy and never using oral anti-
diabetes medications as having type 1 diabetes. Our clas-
sification differed in that we defined our type 1 cohort
using incentivised diagnostic codes and additional demo-
graphic factors to age and insulin prescriptions. Leegaard
et al had very small numbers of patients classified with
type 1 diabetes, only three amongst their TB cases and
the adjusted TB risk estimate reflected the imprecision
(OR 2.59, 0.44–15.29). Similarly, we found only one case
of TB amongst our group of patients classified with type
1 diabetes and, thus, we were unable to explore the ef-
fects of type 1 diabetes further. Under-ascertainment of
TB in type 1 diabetes patients within CPRD is a possible
cause of our finding only one case of TB in this group.
This might be due to those with type 1 diabetes mainly
receiving their care in hospital out-patients clinics and
notification of TB diagnoses not being returned to gen-
eral practice. If a large number of cases of TB in the UK
are due to reactivation of latent disease from those born
in high TB burden countries [2, 1], it might be that
Table 4 Estimatesa of effect of diabetes on absolute tuberculosis incidence ratesb
Low risk groupc High risk groupd
With diabetes Without diabetes Difference With diabetes Without diabetes Difference
Tuberculosis ratesb 3.7 × 10−6 2.8 × 10−6 8.4 × 10−7 893.7 687.9 205.8
aIncidence rates predicted from Poisson model including variables: diabetes status, age, ethnicity, alcohol status, smoking status, body mass index (BMI) and index
of multiple deprivation (IMD)
bTuberculosis rates per 100,000 person years
cAge <20 years, white ethnicity, moderate drinkers, non-smokers, BMI >30 and in the 1st IMD quintile
dAge >70 years, South Asian ethnicity, non-drinkers, current-smokers, BMI <20 and in the 5th IMD quintile
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Table 5 Effect of diabetes (DM) on rate of tuberculosis, modification by consultation rate, consultation number, age, time since
diagnosis of diabetes and ethnicity
Strata Exposure
status
TB cases/
PYa
Unadjusted rate Unadjusted rate ratio Adjusted rate ratiob P-value for
interactionc(95 % CI) (95 % CI) (95 % CI)
Consultation rated
1st tertile DM 5/0.93 5.35 (2.23–12.86) 0.91 (0.37–2.22) 1.80 (0.64–5.01)
Non-DM 141/23.94 5.89 (4.99–6.95) 1.0 1.0
2nd tertile DM 39/4.61 8.46 (6.18–11.59) 0.65 (0.46–0.91) 1.01 (0.63–1.62) 0.535
Non-DM 273/20.92 13.05 (11.59–14.69) 1.0 1.0
3rd tertile DM 146/6.19 23.60 (20.01–27.76) 0.83 (0.68–1.00) 0.94 (0.69–1.27)
Non-DM 265/12.81 28.50 (25.72–31.57) 1.0 1.0
Consultation numbere
1st tertile DM 48/0.35 138.41 (104.31–183.67) 5.14 (3.78–7.00) 2.99 (1.68–5.31)
Non-DM 254/9.43 26.93 (23.82–30.46) 1.0 1.0
2nd tertile DM 70/1.97 35.61 (28.17–45.01) 2.42 (1.86–3.14) 2.88 (1.96–4.24) 0.003
Non-DM 285/19.37 14.71 (13.10–16.53) 1.0 1.0
3rd tertile DM 72/9.42 7.65 (6.07–9.63) 0.92 (0.71–1.20) 1.26 (0.87–1.83)
Non-DM 240/28.87 8.31 (7.32–9.43) 1.0 1.0
Age in years
0- < 45 DM 10/1.10 9.07 (4.88–16.86) 1.23 (0.61–2.45) 0.97 (0.32–2.93)
Non-DM 41/5.54 7.40 (5.45–10.04) 1.0 1.0
45- < 70 DM 103/6.11 16.85 (13.89–20.45) 1.71 (1.37–2.14) 1.62 (1.14–2.31) 0.228
Non-DM 295/29.93 9.86 (8.79–11.05) 1.0 1.0
70+ DM 77/4.51 17.0 (13.64–21.32) 0.85 (0.67–1.09) 1.08 (0.76–1.55)
Non-DM 443/22.20 19.95 (18.18–21.90) 1.0 1.0
Time since index date
0- < 1 years DM 56/2.07 27.07 (20.83–35.17) 1.83 (1.35–2.48) 1.48 (0.86–2.56)
Non-DM 165/11.16 14.78 (12.69–17.22) 1.0 1.0
1- < 5 years DM 80/5.72 13.99 (11.24–17.41) 0.99 (0.78–1.26) 1.24 (0.88–1.74) 0.375
Non-DM 407/28.81 14.13 (12.82–15.57) 1.0 1.0
5- < 10 years DM 41/3.08 13.32 (9.80–18.08) 1.05 (0.75–1.48) 1.13 (0.68–1.87)
Non-DM 177/14.01 12.64 (10.91–14.64) 1.0 1.0
10+ years DM 13/0.86 15.11 (8.77–26.02) 1.86 (0.97–3.57) 2.66 (1.12–6.35)
Non-DM 30/3.70 8.11 (5.67–11.61) 1.0 1.0
Ethnicity
White DM 74/6.74 10.98 (8.74–13.79) 0.88 (0.69–1.13) 1.27 (0.95–1.69)
Non-DM 380/30.57 12.43 (11.24–13.75) 1.0 1.0
South Asian DM 38/0.27 139.40 (101.43–191.58) 1.39 (0.91–2.12) 1.34 (0.79–2.28) 0.894
Non-DM 49/0.49 100.58 (76.02–133.08) 1.0 1.0
Black, Mixed or Other DM 5/0.20 24.41 (10.16–58.65) 0.57 (0.22–1.49) 1.65 (0.55–4.93)
Non-DM 26/0.61 42.74 (29.10–62.77) 1.0 1.0
aPY: 100,000 person years at risk
bModel adjusted for: age, ethnicity, BMI, alcohol status, smoking and IMD
cP-value from likelihood ratio test
dConsultation rate defined as number of face to face consultations per year of follow-up; tertiles in order of increasing consultation rate
eConsultation number defined as total number of face to face consultations during patient follow-up; tertiles in order of increasing number of consultations
BMI body mass index, CI confidence interval, IMD index of multiple deprivation, TB tuberculosis
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incidence of type 1 diabetes in these populations is low,
as supported by global incidence studies [34] or that
these patients suffer competing risks before possible re-
activation of TB infection.
Current UK guidelines advise considering treatment
for latent TB infection in certain groups of adults where
active disease has been ruled out but they show signs of
TB infection with Mantoux positivity (≥6 mm) and with-
out prior Bacillus Calmette-Guérin (BCG) vaccination,
or strong Mantoux positivity (≥15 mm) or interferon-
gamma release assay (IGRA) positive and with prior
BCG vaccination [35]. There is no specific guidance for
patients with diabetes at present.
Strengths and limitations
To our knowledge, this is the largest cohort study to
date exploring the association between diabetes and TB
in a general population which was able to adjust for im-
portant individual level confounding demographic, socio-
economic and lifestyle factors. By using time-updated
exposure status, where previous unexposed patients could
later develop incident diabetes and join the exposed co-
hort, we could study time-related phenomena but our
design also allowed comparison between more similar
groups ensuring we could explore the role of diabetes with
reduced confounding from unmeasured social and health-
related risk factors. Previous literature describe excluding
Table 6 Comparison of rates of tuberculosis in 216,545 patients with type 2 diabetes (T2DM) categorised by health care utilisation
with a matched unexposed cohort
Age adjusted Fully adjusted modela
Exposure group Number of patients TB cases/
PYb
Ratec (95 % CI) Rate ratio Rate ratio P-value*
(% of T2DM) (95 % CI) (95 % CI)
Patients without diabetes 1,186,844 764/55.87 13.67 (12.74–14.68) 1.00 1.00
Patients with T2DM
Cholesterol testing rate:
Less than once per year 89,989 (41.6) 116/4.42 26.23 (21.87–31.46) 1.91 (1.58–2.33) 1.78 (1.29–2.44) <0.001
Once per year 88,961 (41.1) 44/5.52 7.97 (5.93–10.71) 0.58 (0.43–0.79) 0.76 (0.50–1.14)
Twice or more per year 37,595 (17.3) 29/1.44 20.16 (14.01–29.01) 1.47 (1.02–2.14) 1.98 (1.20–3.27)
Blood pressure testing rate:
Up to once per year 41,839 (19.3) 55/1.94 28.30 (21.73–36.86) 2.34 (1.78–3.07) 2.49 (1.59–3.92) <0.001
Once to twice per year 55,983 (25.9) 27/3.36 8.03 (5.51–11.72) 0.60 (0.41–0.88) 0.67 (0.38–1.18)
More than twice per year 118,723 (54.8) 108/6.42 16.81 (13.92–20.30) 1.23 (1.00–1.50) 1.34 (0.99–1.81)
Influenza vaccination rate:
Less than once per year 57,257 (26.4) 84/2.35 35.62 (28.76–44.11) 2.61 (2.08–3.26) 2.91 (2.00–4.23) <0.001
Once per year 159,288 (73.6) 105/9.02 11.64 (9.61–14.09) 0.85 (0.69–1.04) 0.98 (0.73–1.32)
*P-value from likelihood ratio test
aModel adjusted for: age, BMI, smoking status, alcohol status, ethnicity and IMD
bPY: 100,000 person years at risk
cRate: per 100,000 person years
BMI body mass index, CI confidence interval, IMD index of multiple deprivation, TB tuberculosis
Table 7 Comparing rates of tuberculosis in 216,545 patients with type 2 diabetes (T2DM) by time-dependent treatment group with
a matched unexposed cohort
Crude Fully adjusted modela
Exposure group Number of patients TB cases/
PYb
Ratec (95 % CI) Rate ratio Rate ratio P-value*
(% of T2DM) (95 % CI) (95 % CI)
Patients without diabetes 1,186,932 765/55.87 13.69 (12.76–14.70) 1.00 1.00
Patients with T2DM:
Without insulin exposure 190,865 (88.1) 161/10.05 16.02 (13.72–18.69) 1.16 (0.98–1.37) 1.27 (0.98–1.66) 0.119
During insulin exposure 25,680 (11.9) 28/1.33 21.07 (14.55–30.51) 1.63 (1.12–2.38) 1.49 (0.83–2.67)
*P-value from likelihood ratio test
aModel adjusted for: age, BMI, smoking status, alcohol status, ethnicity and IMD
bPY: 100,000 person years at risk
c Rate: per 100,000 person years
BMI body mass index, CI confidence interval, IMD index of multiple deprivation, TB tuberculosis
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people with prior diagnoses of tuberculosis but we in-
cluded this group with a suitable time-lapse as they will be
amongst the highest risk groups for TB disease in the UK
so our findings are more applicable to the population of
interest.
Our study explores effects of important patient charac-
teristics such as age and ethnicity and aspects of the risk
factor of diabetes such as duration and severity, which
have not been previously explored within one cohort. As
far as we are aware this is the only study to look at how
TB risk for diabetes patients varies with consultation
patterns including receipt of chronic disease health care
and shows how UK General Practice systems are able to
identify different risk groups. The study is based within
the General Practice population using routinely collected
clinical data so reducing the likelihood of significant se-
lection bias. In the UK the majority of diabetes care oc-
curs in the primary care setting making our cohort of
diabetes patients very inclusive. Where patients receive
specialist diabetes care in the face of more challenging dis-
ease control, their primary care record is equally import-
ant and contemporaneous as primary care co-ordinates
ongoing management, such as retinal screening and im-
munisation. Our study is pertinent to any UK policy seek-
ing to identify high-risk groups in primary care suitable
for latent TB infection screening using such routine elec-
tronic health data.
There is the potential for misclassification of diabetes
and TB within our study as we used routinely collected
clinical data without validation from consultation free text
or hospital correspondence. We expect misclassification
to be minimal as diabetes is an indicator condition within
UK Primary Care; thus, practices are incentivised to main-
tain accurate diabetes patient registers. Seventy percent of
our cohort with diabetes had confirmatory prescription
data for anti-diabetic medications and the 30 % having
no specific therapy but other recorded indicators is in
agreement with previous studies [36]. We generated a spe-
cific TB Read code list to try to avoid the inclusion of
non-mycobacterial disease. Although TB can present non-
specifically initially we would expect patients to seek med-
ical attention in a setting with free access to health care.
Diagnoses of TB made in secondary care are highly likely
to be communicated to the General Practitioner due to
the public health risk of this communicable disease, the
risk of serious side-effects from antituberculous therapy
and possible treatment interactions with medications pre-
scribed in primary care. We found an incidence of TB in
our unexposed cohort that was equal to that reported as
the UK TB incidence for 2012 (13.9 cases per 100,000
population) [2], therefore supporting that we reliably iden-
tified cases of TB. Any misclassification of our outcome is
likely to be non-differential as unexposed patients could
join the exposed group during follow-up and “inactive”
controls were excluded who are more likely to be misclas-
sified as unexposed. Furthermore, there is no current UK
guideline advising screening of patients with diabetes for
TB and broader awareness for the association between the
two conditions was only recently raised [37], thus any bias
will tend towards underestimating associations.
There is a risk of reverse causality with diagnoses made
close together and with a condition such as TB which may
initially present with non-specific symptoms and can itself
cause a reactive hyperglycaemia associated with acute in-
fection [38]. TB diagnosis and treatment delays can be as
long as three months in high-income settings [39, 40] but
potential delays in diagnosis of diabetes far exceed this
with estimates between four to seven years [41]. Thus, it is
far more likely in the situation where a diagnosis of TB
closely follows a diagnosis of diabetes that the condition
of diabetes or chronic hyperglycaemia has been ongoing
for some time previous. Using similar considerations, we
did not introduce a minimum follow-up time after dia-
betes diagnosis. There is no current evidence-base to
Table 8 Comparing rates of tuberculosis in 198,227 patients with type 2 diabetes (T2DM) and HbA1c measurements with a
matched unexposed cohort
Age adjusted Fully adjusted modela
Exposure group Number of patients TB cases/
PYb
Ratec (95 % CI) Rate ratio Rate ratio P-value*
(% of T2DM) (95 % CI) (95 % CI)
Patients without diabetes 1,088,376 689/50.97 13.51 (12.54–14.56) 1.00 1.00
Patients with T2DM
HbA1c mmol/mol (%):
≤48 (6.5) 61,336 (30.9) 50/2.86 17.48 (13.25–23.06) 1.29 (0.97–1.72) 1.34 (0.88–2.05) 0.140
49-≤ 58 (6.5–7.5) 70,470 (35.6) 54/3.98 13.57 (10.39–17.72) 1.00 (0.76–1.32) 1.14 (0.76–1.70)
>58 (>7.5) 66,421 (33.5) 71/3.99 17.81 (14.12–22.48) 1.32 (1.03–1.68) 1.50 (1.04–2.17)
*P-value from likelihood ratio test
aModel adjusted for: age, BMI, smoking status, alcohol status, ethnicity and IMD
bPY: 100,000 person years at risk
cRate: per 100,000 person years
BMI body mass index, CI confidence interval, IMD index of multiple deprivation, TB tuberculosis
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guide us in considering a mechanistically plausible mini-
mum length of follow-up within which TB risk increases
and introducing an arbitrary follow-up time will only pro-
duce survivor bias.
Information on country of origin is not routinely re-
corded within the primary care clinical record and may
confound the association between diabetes and TB. Life-
style factors predisposing a person to diabetes associated
with the country of origin are likely superseded by those
associated with residence in the UK and remaining life-
style factors or genetic predisposition could be crudely
captured by ethnicity descriptors. However, there is likely
residual confounding especially as ethnicity was only
broadly described within our study. We did not identify
and adjust for HIV status within our study as this is recog-
nised to be under-reported in General Practice records
[42]. HIV and its treatment have been associated with
metabolic derangement including diabetes [43] and HIV is
a strong risk factor for TB disease [44, 45]. We did not
identify and exclude patients with recorded HIV as this
may have differentially affected TB patients with diabetes
as we expected these patients might be more likely to
share a diagnosis of HIV with their General Practitioner
due to the risk of multiple drug interactions between their
HIV and diabetes medications. We did not adjust for BCG
vaccination status. The UK immunisation program rec-
ommends childhood BCG immunisation for those at
higher risk of TB [46]. The protection offered by BCG im-
munisation wanes with time [47], and is likely to offer lit-
tle protection to the age groups predominantly at risk of
TB associated with diabetes.
We performed multiple imputation for missing data on
important covariates but there is likely residual confound-
ing from non-differential misclassification of these data.
Our main findings were robust to the inclusion of im-
puted missing data. There were fewer missing data for
patients with diabetes, which is to be expected as these
represent a group that are better characterised within rou-
tine primary care data. Missing data produce loss of study
power, despite multiple imputation methods, which calcu-
late standard errors reflecting the increased uncertainty.
The study also had insufficient power, risking type 2 error,
for the investigation of some interactions as we had small
numbers of outcome data in some of our subgroup ana-
lyses. Thus, larger well-characterised cohorts in higher TB
incidence settings would be needed to study these possible
interactions.
Conclusions and public health implications
We find evidence for an increased risk of TB amongst
those with diabetes but in contrast with many other
studies mostly from high TB burden countries, the risk
is only modest in our UK General Practice population.
Our findings may reflect good management of diabetes
in UK primary care and, therefore, reduced attendant in-
fection risks from this chronic condition. Diabetes alone
is not a sufficient indication for screening for latent TB
infection in the UK. Importantly we also identified a
group of patients with diabetes and reduced primary
health care utilisation who are at increased risk of TB. It
appears these might form a higher risk hard to reach
group in terms of accessing them through primary care.
Our findings can inform the development of such a pri-
mary care latent TB infection screening program hoping
to reach high-risk groups and how effective such an ap-
proach might be for improving UK TB control.
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